151 related articles for article (PubMed ID: 32961814)
1. A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells.
Cho H; Chung JS; Han KH
Micromachines (Basel); 2020 Sep; 11(9):. PubMed ID: 32961814
[TBL] [Abstract][Full Text] [Related]
2. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation for somatic mutation detection in circulating tumor cells isolated using a lateral magnetophoretic microseparator.
Cho H; Kim J; Han SI; Han KH
Biomed Microdevices; 2016 Oct; 18(5):91. PubMed ID: 27628059
[TBL] [Abstract][Full Text] [Related]
4. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
5. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Kasimir-Bauer S; Keup C; Hoffmann O; Hauch S; Kimmig R; Bittner AK
Front Oncol; 2020; 10():1658. PubMed ID: 33014830
[No Abstract] [Full Text] [Related]
7. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
8. Effective Circulating Tumor Cell Isolation Using Epithelial and Mesenchymal Markers in Prostate and Pancreatic Cancer Patients.
Cha J; Cho H; Chung JS; Park JS; Han KH
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345161
[TBL] [Abstract][Full Text] [Related]
9. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.
Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; De Souza P; Becker TM
Cells; 2019 Jul; 8(7):. PubMed ID: 31288377
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
11. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
[TBL] [Abstract][Full Text] [Related]
13. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
[TBL] [Abstract][Full Text] [Related]
14. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
15. Cancer panel analysis of circulating tumor cells in patients with breast cancer.
Lee CH; Lee SJ; Choi SH; Ahn SH; Son BH; Lee JW; Yu JH; Kwon NJ; Lee WC; Yang KS; Lee DH; Han DY; Choi MS; Park PS; Lee HK; Kim MS; Lee J; Jeon BH
Oncol Lett; 2018 Jul; 16(1):612-618. PubMed ID: 29928447
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
[TBL] [Abstract][Full Text] [Related]
17. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cell microseparator based on lateral magnetophoresis and immunomagnetic nanobeads.
Kim S; Han SI; Park MJ; Jeon CW; Joo YD; Choi IH; Han KH
Anal Chem; 2013 Mar; 85(5):2779-86. PubMed ID: 23384087
[TBL] [Abstract][Full Text] [Related]
19. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs).
Hyun KA; Lee TY; Lee SH; Jung HI
Biosens Bioelectron; 2015 May; 67():86-92. PubMed ID: 25060749
[TBL] [Abstract][Full Text] [Related]
20. An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood.
Chelakkot C; Ryu J; Kim MY; Kim JS; Kim D; Hwang J; Park SH; Ko SB; Park JW; Jung MY; Kim RN; Song K; Kim YJ; Choi YL; Lee HS; Shin YK
Micromachines (Basel); 2020 May; 11(6):. PubMed ID: 32486306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
